Barclays PLC grew its position in Crispr Therapeutics AG (NASDAQ:CRSP) by 42.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 13,877 shares of the company’s stock after purchasing an additional 4,151 shares during the period. Barclays PLC’s holdings in Crispr Therapeutics were worth $568,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Nikko Asset Management Americas Inc. grew its position in Crispr Therapeutics by 48.4% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after purchasing an additional 906,006 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares during the last quarter. Wells Fargo & Company MN grew its position in Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares during the last quarter. Morgan Stanley grew its position in Crispr Therapeutics by 6.1% in the 2nd quarter. Morgan Stanley now owns 284,984 shares of the company’s stock worth $13,423,000 after purchasing an additional 16,361 shares during the last quarter. Finally, Royal Bank of Canada grew its position in Crispr Therapeutics by 75.1% in the 2nd quarter. Royal Bank of Canada now owns 120,425 shares of the company’s stock worth $5,672,000 after purchasing an additional 51,665 shares during the last quarter. Hedge funds and other institutional investors own 49.82% of the company’s stock.

In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total transaction of $465,000.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $465,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,118 shares of company stock valued at $3,620,760. Company insiders own 21.40% of the company’s stock.

Several research analysts have recently issued reports on CRSP shares. Goldman Sachs Group increased their price objective on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. Piper Jaffray Companies reiterated a “buy” rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a report on Tuesday, November 26th. Roth Capital increased their price objective on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Canaccord Genuity increased their price objective on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a report on Wednesday, November 20th. Finally, Oppenheimer increased their price objective on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Crispr Therapeutics presently has a consensus rating of “Buy” and an average price target of $69.54.

CRSP stock opened at $65.65 on Thursday. Crispr Therapeutics AG has a 12 month low of $22.22 and a 12 month high of $74.00. The firm has a market cap of $4.00 billion, a PE ratio of -19.08 and a beta of 3.30. The firm has a 50 day simple moving average of $57.87 and a 200 day simple moving average of $48.15. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32.

Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. As a group, sell-side analysts expect that Crispr Therapeutics AG will post 0.65 earnings per share for the current year.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

See Also: Understanding each part of a balance sheet

Institutional Ownership by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link